#Immunic

Thiard News@F4F

@newsen.bsky.social

6 days ago

Immunic Secures Key European Patent for Vidofludimus Calcium Dosing Regimens Immunic, Inc. gains a significant European patent for vidofludimus calcium, enhancing its intellectual property strategy and market exclusivity.

Immunic Secures Key European Patent for Vidofludimus Calcium Dosing Regimens #United_States #New_York #Patent #Immunic #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Immunic, Inc. Boosts Position in Neuroscience with Major Financial Update for 2025 Immunic, Inc. has shared its impressive 2025 financial results alongside major updates on drug trials and corporate growth, showcasing its potential.

Immunic, Inc. Boosts Position in Neuroscience with Major Financial Update for 2025 #United_States #New_York #biotechnology #Immunic #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

1 month ago

Immunic Secures $400 Million Funding to Transform Into Commercial-Stage Biotech Firm Immunic, Inc. has announced a successful $400 million private placement to advance its transition from a research-focused to a commercial-stage biotechnology company.

Immunic Secures $400 Million Funding to Transform Into Commercial-Stage Biotech Firm #United_States #New_York #biotechnology #Immunic #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

1 month ago

Immunic Showcases Promising Phase 2 CALLIPER Data for Vidofludimus Calcium at 2026 ACTRIMS Forum Immunic, Inc. to present new findings from the Phase 2 CALLIPER trial of Vidofludimus Calcium at the upcoming ACTRIMS Forum 2026, emphasizing its potential in treating progressive multiple sclerosis.

Immunic Showcases Promising Phase 2 CALLIPER Data for Vidofludimus Calcium at 2026 ACTRIMS Forum #United_States #San_Diego #Multiple_Sclerosis #Immunic #Vidofludimus_Calcium

Thiard News@F4F

@newsen.bsky.social

2 months ago

Immunic's 2025 Achievements and Future Goals in MS Treatment Unveiled Immunic, Inc. outlines significant milestones from 2025, including advancements in multiple sclerosis therapies and future developmental plans targeting MS and gastrointestinal disorders.

Immunic's 2025 Achievements and Future Goals in MS Treatment Unveiled #USA #New_York #Immunic #IMU-856 #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

3 months ago

Immunic's Participation in Evercore ISI Healthcare Conference to Share Insights on Innovative Therapies Immunic, Inc. will showcase its innovative therapies at the 8th Annual Evercore ISI Healthcare Conference on December 4, 2025. Tune in for updates!

Immunic's Participation in Evercore ISI Healthcare Conference to Share Insights on Innovative Therapies #USA #Immunic #Vidofludimus #IMUX #Coral_Gables,_FL

Thiard News@F4F

@newsen.bsky.social

4 months ago

Immunic, Inc. Reports Encouraging Q3 2025 Results and Future Milestones on Vidofludimus Calcium Immunic, Inc. released its Q3 2025 financial results, highlighting significant advancements in Vidofludimus Calcium for treating multiple sclerosis.

Immunic, Inc. Reports Encouraging Q3 2025 Results and Future Milestones on Vidofludimus Calcium #United_States #New_York #Immunic #Vidofludimus_Calcium #MS_Treatment

Thiard News@F4F

@newsen.bsky.social

4 months ago

Immunic's Upcoming Participation in Key Investor Conferences This November Immunic, Inc. will engage in vital industry conferences this November, discussing advancements in its innovative therapies for autoimmune diseases.

Immunic's Upcoming Participation in Key Investor Conferences This November #USA #New_York #Immunic #IMUX #therapies

Thiard News@F4F

@newsen.bsky.social

5 months ago

Immunic Announces Participation in Key Scientific and Investor Conferences This October Immunic, Inc. will present significant findings on its innovative therapies for chronic diseases at multiple conferences in October, enhancing investor engagement.

Immunic Announces Participation in Key Scientific and Investor Conferences This October #United_States #New_York #Immunic #IMU-856 #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

5 months ago

Immunic Showcases Promising Vidofludimus Calcium Data at ECTRIMS 2025 At ECTRIMS 2025, Immunic presented significant findings on Vidofludimus Calcium, showing its potential to improve disability in multiple sclerosis patients.

Immunic Showcases Promising Vidofludimus Calcium Data at ECTRIMS 2025 #USA #New_York #Immunic #Vidofludimus #ECTRIMS_2025

Thiard News@F4F

@newsen.bsky.social

6 months ago

Immunic's Patent Approval Marks Milestone for Vidofludimus Calcium in Multiple Sclerosis Treatment Immunic, Inc. has secured a U.S. patent for Vidofludimus Calcium, critical for treating progressive multiple sclerosis, offering significant market protection.

Immunic's Patent Approval Marks Milestone for Vidofludimus Calcium in Multiple Sclerosis Treatment #United_States #New_York #Multiple_Sclerosis #Immunic #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

6 months ago

Immunic, Inc. to Showcase Innovations at Upcoming September Conferences Immunic, Inc., a biotechnology firm, will participate in crucial investor and scientific conferences in September 2025, presenting their innovations.

Immunic, Inc. to Showcase Innovations at Upcoming September Conferences #USA #New_York #Immunic #Vidofludimus #Conferences

Thiard News@F4F

@newsen.bsky.social

7 months ago

Immunic, Inc. Reveals Promising Second Quarter Results and Drug Advancements Immunic, Inc. has reported significant clinical advancements and financial results for the second quarter of 2025, including updates on its lead drug, vidofludimus calcium.

Immunic, Inc. Reveals Promising Second Quarter Results and Drug Advancements #USA #New_York #Multiple_Sclerosis #Immunic #Vidofludimus_Calcium

Thiard News@F4F

@newsen.bsky.social

8 months ago

Immunic Presents Promising Long-Term Data on Vidofludimus Calcium for MS Patients at Phase 2 EMPhASIS Trial Immunic, Inc. has revealed new long-term data from the Phase 2 EMPhASIS trial for Vidofludimus Calcium, showcasing its efficacy in managing relapsing-remitting MS.

Immunic Presents Promising Long-Term Data on Vidofludimus Calcium for MS Patients at Phase 2 EMPhASIS Trial #USA #New_York #Multiple_Sclerosis #Immunic #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

9 months ago

Immunic Completes Enrollment for Phase 3 Trials of Vidofludimus Calcium in Multiple Sclerosis Immunic, a biotechnology firm, has concluded participant enrollment for its Phase 3 ENSURE trials exploring vidofludimus calcium in relapsing multiple sclerosis, signaling progress in treatment options.

Immunic Completes Enrollment for Phase 3 Trials of Vidofludimus Calcium in Multiple Sclerosis #United_States #New_York #Multiple_Sclerosis #Immunic #Vidofludimus_Calcium

Thiard News@F4F

@newsen.bsky.social

9 months ago

Immunic, Inc. Successfully Completes $65 Million Public Offering to Fuel Chronic Disease Therapies Immunic, Inc. has announced the successful closing of a $65 million public offering, which will enhance its development of therapies for chronic inflammatory diseases.

Immunic, Inc. Successfully Completes $65 Million Public Offering to Fuel Chronic Disease Therapies #United_States #New_York #biotech #pharmaceuticals #Immunic

Thiard News@F4F

@newsen.bsky.social

9 months ago

Immunic Inc. Set to Showcase Innovations at Multiple Upcoming Conferences Immunic, Inc. will present key findings and engage with industry leaders at several conferences this June. Stay informed about their advancements.

Immunic Inc. Set to Showcase Innovations at Multiple Upcoming Conferences #USA #New_York #biotech #Immunic #Conferences

Thiard News@F4F

@newsen.bsky.social

9 months ago

Immunic, Inc. Successfully Raises $65 Million in Oversubscribed Public Offering Immunic, Inc. has announced the pricing of a highly oversubscribed public offering, attracting $65 million to advance their clinical pipeline.

Immunic, Inc. Successfully Raises $65 Million in Oversubscribed Public Offering #United_States #New_York #Inc. #biotechnology #Immunic #IMUX

Thiard News@F4F

@newsen.bsky.social

10 months ago

Immunic's Vidofludimus Calcium Achieves Major Milestones in Reducing Disability in MS Patients Immunic, Inc. announces promising results for Vidofludimus Calcium in reducing disability in Primary Progressive MS patients by 30%.

Immunic's Vidofludimus Calcium Achieves Major Milestones in Reducing Disability in MS Patients #United_States #New_York #Immunic #Vidofludimus #MS_Therapy

Thiard News@F4F

@newsen.bsky.social

11 months ago

Immunic, Inc. Completes $5.1 Million Equity Offering to Advance Pipeline Development Immunic, Inc. successfully closed a $5.1 million registered direct offering to enhance its clinical trials and further its drug development endeavors. This strategic financing will support its innovative therapies targeting chronic inflammatory diseases.

Immunic, Inc. Completes $5.1 Million Equity Offering to Advance Pipeline Development #United_States #New_York #Immunic #Aberdeen_Investments #IMUX

Thiard News@F4F

@newsen.bsky.social

11 months ago

Immunic, Inc. Secures $5.1 Million in Direct Offering Led by Aberdeen Investments Immunic, Inc. has announced a registered direct offering of $5.1 million, to fund its clinical trials and operations, led by Aberdeen Investments.

Immunic, Inc. Secures $5.1 Million in Direct Offering Led by Aberdeen Investments #USA #New_York #Immunic #Aberdeen_Investments #IMUX

Thiard News@F4F

@newsen.bsky.social

1 year ago

Immunic to Showcase Innovative Therapies at Upcoming Conferences This March Immunic, Inc. will present their cutting-edge therapies at two significant conferences in March, including scientific talks and investor meetings.

Immunic to Showcase Innovative Therapies at Upcoming Conferences This March #USA #New_York #Conference #Immunic #Vidofludimus

Thiard News@F4F

@newsen.bsky.social

1 year ago

Immunic Showcases Vidofludimus Calcium Research at ACTRIMS 2025 Forum Immunic, Inc. unveiled detailed findings on Vidofludimus Calcium at the ACTRIMS Forum 2025, offering hope for multiple sclerosis treatments.

Immunic Showcases Vidofludimus Calcium Research at ACTRIMS 2025 Forum #United_States #Multiple_Sclerosis #West_Palm_Beach #Immunic #Vidofludimus_Calcium

Thiard News@F4F

@newsen.bsky.social

1 year ago

New Insights Reveal Immunic's IMU-856 as a Potential Oral Therapy for Weight Management Recent data presents Immunic's IMU-856 as a promising oral treatment for weight management by enhancing GLP-1 levels, showcasing its therapeutic potential.

New Insights Reveal Immunic's IMU-856 as a Potential Oral Therapy for Weight Management #United_States #New_York #GLP-1 #Immunic #IMU-856

Thiard News@F4F

@newsen.bsky.social

1 year ago

Immunic's Promising Advancements in Multiple Sclerosis Research for 2024 In 2024, Immunic Inc. marks significant progress in MS drug development, with key trials and promising outcomes expected soon.

Immunic's Promising Advancements in Multiple Sclerosis Research for 2024 #United_States #New_York #Immunic #Vidofludimus_Calcium #MS_Research